DOI: 10.1136/annrheumdis-2016-eular.4453
View full text |Buy / Rent full text
Sign up to set email alerts

Abstract: BackgroundThe advancement in biological agents (Bio) and improvement in treatment strategy enabled patients with rheumatoid arthritis to achieve remission or to achieve low disease activity. On the other hand, the cost of Bio has become a major problem in health economics and for some patients Bio therapy is not affordable. In this situation, it is important for us to consider whether we should discontinue or extend the interval of Bio.ObjectivesTo investigate Bio-holiday therapy for rheumatoid arthritis patie… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles